Amgen Inc. said its fourth-quarter earnings rose 27%, as sales growth was again driven by key drugs such as cancer therapy drug Kyprolis and osteoporosis treatment Prolia.
via WSJ.com: US Business http://ift.tt/1D6uphL
via WSJ.com: US Business http://ift.tt/1D6uphL
Nessun commento:
Posta un commento